) recently re-launched Vestura (3 mg drospirenone and 0.02 mg
ethinyl estradiol), the company's generic version of
) oral contraceptive, Yaz. Actavis decided to re-launch Vestura
following a favorable ruling by the US Court of Appeals for the
Federal Circuit regarding the RE '564 patent.
Vestura was initially launched in Jan 2012. However, Actavis
had to withdraw the product from the market when the US District
Court for the District of Nevada found the RE '564 patent to be
valid. Actavis had appealed the ruling in the Federal Circuit
which found the patent to be invalid.
Vestura is approved for the prevention of pregnancy and the
treatment of moderate acne in women at least 14 years old only if
the patient is willing to use an oral contraceptive for birth
Bayer recorded Yaz/Yasmin/Yasminelle sales of €1,045 million
in 2012. Actavis estimates that Yaz sales, branded and generic,
for the 12 months ended Feb 28, 2013 were about $347 million in
Indian company Lupin is also looking to launch its generic
version of Yaz - the company's generic version has yet to gain
approval from the US Food and Drug Administration (FDA). Lupin is
currently working on its commercialization plan for generic Yaz
while awaiting FDA approval.
Actavis currently carries a Zacks Rank #3 (Hold). The
favorable court ruling is a positive for the company.
Companies in the generic space that currently look
). Both are Zacks Rank #2 (Buy) stocks.
ACTAVIS INC (ACT): Free Stock Analysis Report
AKORN INC (AKRX): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis
MYLAN INC (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.